Full Press Release Details
Annovis Bio Reports Third Quarter Financial Results and Provides
Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) - via IBN - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or
the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer's
disease (AD) and Parkinson's disease (PD), today announced financial results for the third quarter ended September 30, 2024, and
provided a business update.
"The third quarter was marked by important milestones outlining
the next steps for buntanetap," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "The FDA gave us the
green light to initiate confirmatory Phase 3 studies for early AD, and our team has been working hard to begin them in the coming year.
We also strengthened our intellectual property portfolio by filing unique patents protecting new combinations of buntanetap with other
medications for improving cognition."
Cash Runway and Third Quarter 2024 Financial Results
Annovis Bio, Inc. Headquartered in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegeneration in
diseases such as AD and PD. The Company's innovative approach targets multiple neurotoxic proteins, aiming to restore brain function
for Email Alerts at https://www.annovisbio.com/email-alerts.
Statements This press release contains "forward-looking" statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include,
but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and
assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such
risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the
timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap.
Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors"
section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this
press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation
to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required
101 Lindenwood Drive
InvestorBrandNetwork (IBN)